Addison病 中国就医指南

Addison's disease, also known as primary adrenal insufficiency, is a rare, chronic endocrine disorder characterized by inadequate production of cortisol and often aldosterone by the adrenal cortex. This deficiency arises from autoimmune destruction of the adrenal glands in approximately 80–90% of cases in developed countries—where the body’s immune system mistakenly targets and damages adrenal cortical tissue. Other causes include infections (e.g., tuberculosis, HIV-associated mycobacterial or fungal infections), bilateral adrenal hemorrhage, metastatic cancer, genetic disorders (e.g., autoimmune polyglandular syndrome type 1, adrenoleukodystrophy), and surgical removal of the adrenals. The pathogenesis centers on glucocorticoid and mineralocorticoid deficiency: cortisol regulates metabolism, immune response, stress adaptation, and blood pressure; aldosterone maintains sodium-potassium balance and intravascular volume. Without replacement, patients face life-threatening adrenal crises—marked by profound hypotension, hyponatremia, hyperkalemia, hypoglycemia, vomiting, confusion, and shock. Epidemiologically, Addison’s disease affects about 100–140 per million people globally, with an annual incidence of 4–6 new cases per million. It occurs equally across sexes and most commonly presents between ages 30–50, though it can manifest at any age—including childhood in genetic forms. Risk factors include personal or family history of autoimmune diseases (e.g., type 1 diabetes, Hashimoto’s thyroiditis, vitiligo), prior tuberculosis exposure (especially in endemic regions), HIV infection, antiphospholipid syndrome, and use of anticoagulants predisposing to adrenal hemorrhage. Quality of life is significantly impacted: fatigue, orthostatic dizziness, weight loss, gastrointestinal distress, depression, and reduced exercise tolerance are common—even with treatment. Patients require lifelong hormone replacement and vigilant self-management, including stress-dose steroid adjustment during illness or injury. Psychological burden is substantial due to unpredictability of crises, medication adherence demands, and social stigma around chronic invisible illness. Pregnancy requires specialized endocrinology oversight to prevent maternal-fetal complications. Early diagnosis remains challenging due to nonspecific, insidious symptoms—leading to delays averaging 3–6 months from symptom onset to confirmation via morning serum cortisol, ACTH, and ACTH stimulation test. With timely, individualized glucocorticoid (hydrocortisone or prednisone) and mineralocorticoid (fludrocortisone) replacement, life expectancy approaches normal, but mortality remains elevated compared to the general population—primarily due to delayed crisis recognition and suboptimal dosing.

# Addison病（原发性肾上腺皮质功能减退症）治疗方案与费用明细（内分泌科）

一、非手术/保守治疗（一线标准方案）

适用于确诊患者及所有病情稳定者：

• •糖皮质激素替代：氢化可的松片（生理剂量），日剂量15–25 mg，分2–3次口服；年药费：¥800–¥2,400（国产/进口）
• •盐皮质激素替代：氟氢可的松片0.05–0.2 mg/日；年药费：¥600–¥1,800
• •必要检查：血皮质醇+ACTH、电解质、肾素-醛固酮、24h尿游离皮质醇、肾上腺CT；首年检查费：¥1,200–¥2,800

二、急性肾上腺危象抢救（急诊干预）

适用于感染、创伤、应激诱发危象者：

• •静脉氢化可的松100 mg冲击+持续泵入，补液纠电解质；单次住院抢救费（含ICU监护）：¥8,000–¥25,000（依危重程度及天数浮动）

三、特殊复杂情况处理

• •自身免疫多腺体综合征（APS-1/2）合并者：需同步管理甲状腺炎、1型糖尿病等，年综合随访管理费：¥3,000–¥6,500
• •结核性肾上腺炎继发者：加抗结核治疗（异烟肼+利福平+吡嗪酰胺），全程6–9个月药费：¥1,500–¥3,200

四、方案快速选择指南

• •预算有限/初诊稳定者：首选国产激素替代+年度基础检查（年总支出≈¥3,500–¥6,000）
• •中高预算/追求用药便利性：选用缓释氢化可的松（如Plenadren®）+定期激素监测（年总支出≈¥12,000–¥18,000）
• •危象高风险/术后应激期患者：必须配备应急注射剂（氢化可的松琥珀酸钠）并接受专科教育（一次性培训+备药费≈¥1,200）